- Home
- UCL vs NRXP Comparison
UCL vs NRXP Comparison
Compare UCL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCL | NRXP |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 54.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | UCL | NRXP |
|---|---|---|
| Price | $1.63 | $1.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 7.2K | ★ 571.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.99 | $847.91 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.58 |
| 52 Week High | $4.19 | $3.84 |
Technical Indicators
Market Signals| Indicator | UCL | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 53.07 |
| Support Level | $1.52 | $1.66 |
| Resistance Level | $1.85 | $1.99 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 71.93 | 50.45 |
Price Performance
Historical ComparisonAbout UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data related products to enable personal and enterprise users to access mobile internet in more than 100 countries and areas. Leveraging its inventive cloud SIM technology and architecture, the company redefine the mobile data connectivity experience, allowing users to gain access to mobile data traffic allowance shared by network operators on its marketplace. It has aggregated mobile data traffic allowances from 391 MNOs in 163 countries and regions in its cloud SIM architecture. The company derives maximum revenue from Japan.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.